Screening of high-risk individuals could comprise of a thorough history, clinical examination, blood test panel (C-reactive protein, troponin, B-type natriuretic peptide/NT-proBNP, glycated haemoglobin, lipids), ECG, and transthoracic echocardiography at least 8–12 weeks from infection. This evidence concerns the gene NPPB and infection.